Overview

The fund targets its investments on equities of companies that are domiciled in Switzerland or are included in the SPI.

Criteria for stock selection include the valuation of the company, the business climate, the company`s positioning and the quality of its management.

The long exposure can go up to 130% and the short exposure to -30%.

Benefits

The aim is to outperform the SPI over the long term. Fluctuations in the value of the fund units may differ substantially from those in the SPI.

Risks

This fund invests in equities and may therefore be subject to high fluctuations in value. As these UBS funds pursue an active management style, each fund's performance can deviate from that of its reference index. All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Features

Product category
UBS Country & Regional Funds / Europe
Product domicile
Switzerland
Portfolio management
UBS SA国际传谋 Switzerland AG, Zurich
Fund management
UBS Fund Management (Switzerland) AG
Custodian bank
UBS Switzerland AG, Zurich
Day of inception
December 17, 2004
Currency of account
CHF
Close of financial year
May 31
SFDR Classification
n.a.
Issue / redemption
daily
Distribution
Reinvestment
Maturity
Open end
Ongoing costs p.a.
1.66% p.a.
Management fee
1.00% p.a.
Total expense ratio (TER)
1.07% p.a.
Swing pricing
yes
Minimum investment
n.a.
Reference Index / Benchmark
SPI® (TR) in CHF
Securities no.
1722961
ISIN
CH0017229615
Bloomberg Ticker
CSEQSSA SW
Reuters Id
1722961X.CHE

Performance and Prices

Percentage growth

as of April 23, 2026
Cumulative
CHF(%) EUR(%) USD(%)
YTD 3.29 4.73 4.43
1M
3M
6M
1Y
2Y 15.54 16.53 32.17
3Y
5Y 25.83 51.48 47.23
ø p.a.5Y 4.70 8.66 8.04

Current data
Net asset value 23.04.2026 CHF 45.47
High - last 12 months 27.02.2026 CHF 46.70
Low - last 12 months 25.09.2025 CHF 39.39
Assets of the unit class in mn 23.04.2026 CHF 79.30
Total product assets in mn 23.04.2026 CHF 267.68
Statistical data
Date
2 years
5 years
Total risk reference index / benchmark 31.03.2026 11.72% 12.29%
Sharpe Ratio 31.03.2026 0.32 0.30
Risk Free Rate 31.03.2026 0.46% 0.40%

Structures

By the 10 largest positions (in %, as of March 31, 2026)

 
 
Roche Holding AG 16.02
Nestle SA 13.42
Novartis AG 12.76
Zurich Insurance Group AG 7.56
UBS Group AG 7.17
ABB Ltd 6.32
Swiss Re AG 4.58
Cie Financiere Richemont SA 3.99
Lonza Group AG 3.24
Amrize Ltd 2.98

Fees

Ongoing costs p.a.
1.66%
Flat fee
n.a.
Management fee p.a.
1.00%
Max. redemption commission
2.00%
Max. issuing commission
5.00%
Distribution fee
(see info)

Distributions

No distributions. Continuous reinvestment of income.

Sales Authorisations

Market
Sales authorisations status
Singapore
Institutional Only*
Switzerland
Registered

Literature

en
de
fr
it
es
Brochures
Document type
Document Language
Fact Sheet
it it
fr fr
en en
de de
es es
Manager Commentary
de de
fr fr
en en
ASIP ESG Report
Fact Sheet - UBS Country & Regional Funds / Europe
de de
en en
it it
es es
fr fr
Agreement / Prospectus
Document type
Document Language
Prospectus
Key Information Document
Past performance
Previous performance scenario
Annual and semi-annual report (accounting on May 31)
Document type
Document Language
Annual report
Semi-annual report
General information
Document type
Document Language
Tax list
Please wait for the requested content to load. If there is no response after several minutes, please reload the page or try again later.